Azurity Pharmaceuticals, Inc., a US-based privately-held pharmaceutical company, announced on Wednesday that it has completed the acquisition of Slayback Pharma LLC, a New Jersey-based company focused on complex generic and specialty pharmaceutical products, from present investors including KKR, a global investment firm, and Everstone Capital.

With this acquisition, Slayback has become the wholly-owned subsidiary of Azurity.

This transaction merges both companies' complementary strengths, improving Azurity's ability to realise its purpose of Serving Overlooked Patients. The integrated development portfolios are expected to yield a significant number of new medicine launch over the coming years.

Greenhill & Co. served as financial advisor and White & Case served as legal advisor to Azurity. Leerink Partners served as lead financial advisor and Raymond James as co-advisor to Slayback while Kirkland & Ellis served as legal advisor to Slayback.